Precipio (PRPO) 10-Q2011 Q1 Quarterly report

Filed: 13 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	7th grade Avg

New words: academic, accreted, accurate, achievement, affiliated, affirmative, aggregate, annum, appoint, approach, Asia, asset, assignment, automation, bankruptcy, billing, biotechnology, Black, blood, BRAF, bring, calendar, Certificate, chromatography, closed, combination, combining, competing, compound, comprised, conclusion, Connecticut, connection, consummate, consummation, criteria, Data, debt, declared, default, Delaware, discovered, earlier, earned, efficiency, embarked, embedded, expansion, expert, explore, FAMILION, family, faster, feature, final, footprint, formula, forward, framework, fully, goodwill, growing, Haven, hierarchy, holder, Ice, identical, inactive, integration, karyotyping, key, larger, lead, lesser, line, LLC, mandatorily, matured, met, monthly, mtDNA, newest, noteworthy, offer, pay, PGxHealth, pharmacogenomic, piggyback, post, presence, principal, promissory, proprietary, pursuant, quoted, recurrence, registration, resale, resistance, roll, routine, saliva, sample, Sanger, saving, set, shrinking, source, straight, suffering, technique, thereon, throughput, today, transpired, treatment, twelve, ultra, undergoing, underlying, unobservable, unpaid, validate, warning

Removed: adequate, afford, alleging, assessed, categorized, central, compliant, compliment, coverage, credibility, deficit, demonstrate, developed, developing, Dollar, end, enrichment, Excluding, exist, failing, Finite, flagship, flat, focused, front, gaining, Good, Great, highest, HPLC, inaccurate, Incentive, innovative, Litigation, maximum, medical, minimal, mitochondrial, mix, momentum, negligence, newly, nucleic, opportunity, pharmocogenomic, Potential, prove, purification, rapidly, recovery, reimbursement, reputation, resulted, resulting, substantial, therapy, true, unique

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRPO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Transgenomic, Inc. for the quarter ended March 31, 2011, I, Craig J. Tuttle, Chief Executive Officer of Transgenomic, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

(1)

Such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the quarter ended March 31, 2011, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the quarter ended March 31, 2010, fairly presents, in all material respects, the financial condition and results of operations of Transgenomic, Inc.

/s/ CRAIG J. TUTTLE

Craig J. Tuttle

President and Chief Executive Officer

Date: May 13, 2011

A signed original of the certification required by Section 906 has been provided to Transgenomic, Inc. and will be retained by Transgenomic, Inc and furnished to the Securities and Exchange Commission or its staff upon request.